BioNTech Results Presentation Deck

Expanding our Capabilities and Pipeline in Infectious Diseases ● ● COVID-19 37 mRNA COVID-19 vaccine More than 2 billion doses shipped world-wide Addressing Infectious Diseases with Significant Global Impact ● 8 Seasonal Flu vaccine: Phase 1 trial initiated Q3 • Licensed to Pfizer Eligible for milestone payments and royalties through Pfizer agreement HIV Multiple product candidates in Preclinical development Influenza Vaccines and Ribologicals Collaboration with Bill & Melinda Gates Foundation ● ● mRNA-based Malaria vaccine candidate Malaria Expected Phase 1 start: 2H 2022 • Sustainable end-to-end vaccine supply solutions in Africa planned 5 Additional Non-disclosed Programs Multiple product candidates in preclinical development Vaccines and Ribologicals ob Tuberculosis vaccine candidate Expected Phase 1 start: 2H 2022 • Collaboration with Bill & Melinda Gates Foundation Bacterial Infections New class of precision antibacterials in the form of synthetic lysins Potential to address wide range of pathogens Tuberculosis BIONTECH

View entire presentation